-
Merck Announces Promising One-Year Results for Remigromig in Phase 2b/3 Brunello Study
NYSE: $MRK A New Frontier in Autoimmune Research Merck has officially shared positive one-year results from its pivotal Phase 2b/3 Brunello clinical trial. The study is evaluating the safety and efficacy of remigromig, an investigational anti-PD-1 therapy, specifically targeting patients living with moderate-to-severe systemic lupus erythematosus (SLE). Understanding the Brunello Study The Brunello trial is…
-
Biogen’s Litifilimab Shows Promise: New Phase 2 Data in Lupus Treatment
NASDAQ: $BIIB A Potential Breakthrough for Lupus Patients Biogen has recently shared encouraging updates regarding litifilimab, an investigational humanized monoclonal antibody currently being studied for the treatment of Systemic Lupus Erythematosus (SLE). New data presented from a 52-week Phase 2 study highlights the drug’s potential to offer both rapid and durable efficacy for those managing…